| IDEntification of New Predisposition Genes in Differentiated THYroid Cancer (NCT05014698) | Nantes University Hospital | 2022-02-23 |
| Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers (NCT05604963) | University College, London | 2022-02-14 |
| Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET) (NCT04858867) | Leiden University Medical Center | 2022-01-10 |
| Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer (NCT04964284) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-10-06 |
| Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma (NCT05078853) | Soroka University Medical Center | 2021-10-06 |
| Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal (NCT04971473) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-09-10 |
| Targeted Therapy to Increase RAI Uptake in Metastatic DTC (NCT05024929) | Children's Hospital of Philadelphia | 2021-07-16 |
| Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer (NCT04880798) | Peking Union Medical College Hospital | 2021-05-06 |
| Lenvatinib in Locally Advanced Invasive Thyroid Cancer (NCT04321954) | Massachusetts Eye and Ear Infirmary | 2021-03-09 |
| Nomogram for Predicting Difficult Transoral and Submental Thyroidectomy (NCT06671184) | Shanghai 6th People's Hospital | 2021-01-01 |
| The Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China (NCT04857086) | Huazhong University of Science and Technology | 2020-12-30 |
| The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. (NCT04447183) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-11-23 |
| The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer (NCT04563780) | Assiut University | 2020-10-01 |
| Investigating National Solutions for Personalised Iodine-131 Radiation Exposure (NCT04391244) | Royal Marsden NHS Foundation Trust | 2020-06-17 |
| Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer (NCT05789667) | Regina Elena Cancer Institute | 2020-05-27 |
| A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection. (NCT03986437) | Institut Claudius Regaud | 2020-01-13 |
| Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients (NCT04137185) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2019-06-10 |
| Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy (NCT03416686) | Assistance Publique - Hôpitaux de Paris | 2019-04-16 |
| Primary Care Transfer for Thyroid Cancer Patients (NCT03794375) | Hospital de Clinicas de Porto Alegre | 2019-01-01 |
| Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patients (NCT03757637) | National Taiwan University Hospital | 2018-12-01 |
| A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy (NCT03690388) | Exelixis | 2018-10-05 |
| A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer (NCT03602495) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2018-08-29 |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer (NCT03630120) | H. Lee Moffitt Cancer Center and Research Institute | 2018-08-06 |
| CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer (NCT03002623) | National Cancer Institute (NCI) | 2016-12-22 |
| Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer (NCT03048877) | Peking Union Medical College Hospital | 2016-12-01 |
| Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer (NCT02870569) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2016-09-01 |
| Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China (NCT02638077) | Huazhong University of Science and Technology | 2015-10-01 |
| A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer (NCT02244463) | Dana-Farber Cancer Institute | 2015-07-01 |
| Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) (NCT02586337) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2015-07-01 |
| 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis (NCT02304757) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2015-01-01 |
| Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors (NCT03176485) | University of Arizona | 2014-10-17 |
| Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer (NCT01876784) | Genzyme, a Sanofi Company | 2013-09-17 |
| Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer (NCT01843062) | AstraZeneca | 2013-08-27 |
| Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123 (NCT02278198) | University of Colorado, Denver | 2012-11-30 |
| Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors (NCT01700699) | University of Salerno | 2012-10-01 |
| PET Evaluation of Recurrent Differentiated Thyroid Cancer (NCT01641679) | The Netherlands Cancer Institute | 2012-08-01 |
| PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer (NCT03191643) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2011-10-01 |
| Diagnosing Thyroid Cancer Using a Blood Test (NCT01586520) | Newcastle-upon-Tyne Hospitals NHS Trust | 2011-04-01 |
| Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone (NCT01263951) | Thomas Jefferson University | 2010-11-01 |
| Sutent Adjunctive Treatment of Differentiated Thyroid Cancer (NCT00668811) | Medstar Health Research Institute | 2008-04-01 |
| A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. (NCT00295763) | Genzyme, a Sanofi Company | 2006-05-01 |
| No Prognostic or Molecular Disparity Between Synchronous and Metachronous Metastases in Differentiated Thyroid Cancer: Insight From Middle Eastern Cohort (NCT07115810) | King Faisal Specialist Hospital & Research Center | 1988-01-01 |
| An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer (NCT02211222) | Eisai Inc. | |